Adelaide Hebert, MD
Pediatric Dermatology · Bellaire, TXNPI 1427005453
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 51 manufacturers reported payments, led by Pfizer at 31.6% of the total. 2025 is the largest year on record at $420,075, 2.1 times the $195,822 reported in 2019.
Across 1,306 payments — averaging $1137.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$469K
- Incyte Corporation$176K
- Arcutis Biotherapeutics, Inc.$173K
- Sun Pharmaceutical Industries Inc.$125K
- Dermavant Sciences, Inc.$96K
- Galderma Laboratories, L.p.$59K
- plus $388K from 45 others
Across 1,093 payments — averaging $2029.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$631K
- Dermavant Sciences, Inc.$381K
- Takeda Pharmaceuticals U.S.A., Inc.$294K
- Arcutis Biotherapeutics, Inc.$199K
- Amgen$178K
- Incyte Corporation$146K
- plus $388K from 10 others
What the payments were for
- Consulting fees$581,42139%
- Speaking & faculty fees$694,39647%
- Grants$47,7413%
- Travel & lodging$122,1768%
- Food & beverage$38,0443%
- Education$1,2630%
- Gifts$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few pediatric dermatology providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 36 | $725 |
| Triamcinolone Acetonide | 38 | $583 |
| ValacyclovirValacyclovir Hcl | 12 | $287 |
| Minoxidil | 23 | $253 |
Paid to pharmacies, not to this prescriber.
Other pediatric dermatology in Bellaire
- Scarlett BoulosBellaire$2K
- Fred GhaliGrapevine$624K
- Moise LevyAustin$76K
- Neha PuarAustin$23K
- Vicki CarrSpring$22K
- Heather VolkmanFort Worth$9K
- Kerry CarderDallas$4K
- Lucia DiazAustin$4K
- Mark PeakeEl Paso$3K
- Meena JulapalliSpring$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.